VCR-036 / Vicero Bio - LARVOL DELTA

Vicero’s Novel Cancer Immunotherapy Demonstrates Dual-Target Precision with Improved Safety Profile (Businesswire) - "Vicero, Inc...announced compelling safety and efficacy data for VCR-036, its novel dual-targeting immunotherapy candidate. The findings, which demonstrate the potential of this pentavalent PD-1/CTLA-4 antibody to treat solid tumors, have been selected for late-breaker presentation at the inaugural American Association for Cancer Research Immuno-oncology (AACR IO) Conference...Superior safety profile with 100% survival rate compared to 50% survival with standard combination therapy; Complete tumor regression achieved with 5 mg/kg dosing, with sustained remission after tumor rechallenge; Favorable pharmacokinetics supporting potential dosing of ~1 mg flat subcutaneous dose every 6 weeks in humans; Significantly reduced immune-related adverse events compared to combination pembrolizumab/ipilimumab therapy."

Late-breaking abstract • Preclinical • Solid Tumor